Tech Company Financing Transactions
ITBMed Funding Round
ITBMed, based in Stockholm, secured $67 million from private investors.
Transaction Overview
Company Name
Announced On
4/6/2018
Transaction Type
Venture Equity
Amount
$67,000,000
Round
Undisclosed
Investors
private investors (Lead Investor) (Pablo Legorreta)
Proceeds Purpose
This capital injection will be used to develop Siplizumab in its lead indication of induction of tolerance in organ transplantation, where it has been successfully used in a phase II trial to permit organ transplants without the need of lifelong immunosuppression.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Sonja Kovalevskys Gata 4
Stockholm, 113 66
Sweden
Stockholm, 113 66
Sweden
Phone
Website
Email Address
Overview
ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Erik Berglund
Chief Financial Officer
Kasper Granlund
Chief Scientific Officer
David Berglund
Founder
Stefan Berg
Founder
David Sachs
Vice President
Alan Slade
VP - Operations
Kellie Kennon
VP - Regulatory Affairs
Åsa Holmgren
Browse more venture capital transactions:
Prev: 4/6/2018: Summersalt venture capital transaction
Next: 4/6/2018: Knowhere venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs